English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Meeting Abstract

Proteomics identifies CT45 as a mediator of chemosensitivity and immunotherapy target in ovarian cancer.

MPS-Authors
/persons/resource/persons199541

Coscia,  Fabian
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons81010

Bassani-Sternberg,  Michal
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons195388

Wierer,  Michael
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78356

Mann,  Matthias
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Coscia, F., Lengyel, E., Duraiswamy, J., Ashcroft, B., Bassani-Sternberg, M., Wierer, M., et al. (2018). Proteomics identifies CT45 as a mediator of chemosensitivity and immunotherapy target in ovarian cancer. Clinical Cancer Research, 24(15), 95-95.


Cite as: https://hdl.handle.net/21.11116/0000-0001-F7CC-3
Abstract
There is no abstract available